[Bone quality in treatment with raroxifene ].
In recent years, treatments for osteoporosis have been developing rapidly, and many of these research results have been reported. Although the concept of EBM (evidence based medicine) is beginning to become widespread in Japan, the reliability of data can only be composed of reproducibility of trial results and quantitative consistency. Currently, one of trial results considered of possessing the highest reproducibility is the trial result from meta-analysis, which is a synthesis of all trials. Data used on the this meta-analysis is composed of up to 190 researches selected from approximately 2,000 categories of reports, and is the bottom line of osteoporosis treatment data over 25 years. It is believed that this will come forward as indispensable information when suggesting treatments to patients during the course of daily practice.
Nakamura
Toshitaka
T
Department of Orthopaedic Surgery, University of Occupational and Environmental Health.
D015519:Bone Density; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005265:Femoral Neck Fractures / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015201:Meta-Analysis as Topic; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D015203:Reproducibility of Results; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D013739:Testosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013739:Testosterone; D020849:Raloxifene Hydrochloride; D000068296:Risedronic Acid; C016131:testosterone 17 beta-cypionate; D012968:Etidronic Acid